scott eliasof inventions patents and patent applications  justia patents search log in sign up find a lawyer ask a lawyer research the law law schools laws  regs newsletters legal marketing patents by inventor scott eliasof scott eliasof has filed for patents to protect the following inventions this listing includes patent applications that are pending as well as patents that have already been granted by the united states patent and trademark office uspto treatment of cancer publication number  abstract provided are methods relating to compositions that include a cdptopoisomerase inhibitor eg a cdpcamptothecin or camptothecin derivative conjugate eg crlx type application filed may   publication date april   applicant cerulean pharma inc inventors edward g garmey scott eliasof cyclodextrinbased polymers for therapeutic delivery publication number  abstract provided are methods relating to the use of cdptherapeutic agent conjugates for the treatment of a disease or disorder eg autoimmune disease inflammatory disease central nervous system disorder cardiovascular disease or metabolic disorder also provided are cdptherapeutic agent conjugates particles comprising cdptherapeutic agent conjugates and compositions comprising cdptherapeutic agent conjugates type application filed march   publication date march   applicant cerulean pharma inc inventor scott eliasof conjugates particles compositions and related methods of use publication number  abstract particles and conjugates for delivering nucleic acid agents compositions containing the particles the conjugates or both methods of using the particles the conjugates and the compositions type application filed april   publication date july   applicant cerulean pharma inc inventors scott eliasof oliver s fetzer jungyeon hwang patrick lim soo peisze ng sonke svenson donald e bergstrom cyclodextrinbased polymers for therapeutic delivery publication number  abstract provided are methods relating to the use of cdptherapeutic agent conjugates for the treatment of a disease or disorder eg autoimmune disease inflammatory disease central nervous system disorder cardiovascular disease or metabolic disorder also provided are cdptherapeutic agent conjugates particles comprising cdptherapeutic agent conjugates and compositions comprising cdptherapeutic agent conjugates type application filed january   publication date january   applicant cerulean pharma inc inventor scott eliasof conjugates particles compositions and related methods of use publication number  abstract particles and conjugates for delivering nucleic acid agents compositions containing the particles the conjugates or both methods of using the particles the conjugates and the compositions type application filed april   publication date october   applicant cerulean pharma inc inventors scott eliasof oliver s fetzer patrick lim soo peisze ng sonke svenson jungyeon hwang donald bergstrom polymeragent conjugates particles compositions and related methods of use publication number  abstract described herein are polymeragent conjugates and particles which can be used for example in the treatment of cancer also described herein are mixtures compositions and dosage forms containing the particles methods of using the particles eg to treat a disorder kits including the polymeragent conjugates and particles methods of making the polymeragent conjugates and particles methods of storing the particles and methods of analyzing the particles type application filed october   publication date september   applicant cerulean pharma inc inventors thomas c crawford scott eliasof geeti gangal peisze ng lawrence alan reiter compositions and methods for treatment of autoimmune and other disease publication number  abstract provided are methods relating to the use of cdptherapeutic agent conjugates for the treatment of autoimmune disease inflammatory disease or cancer also provided are cdptherapeutic agent conjugates particles comprising cdptherapeutic agent conjugates and compositions comprising cdptherapeutic agent conjugates type application filed november   publication date september   applicant cerulean pharma inc inventor scott eliasof polymeragent conjugates particles compositions and related methods of use publication number  abstract described herein are polymeragent conjugates and particles which can be used for example in the treatment of cancer also described herein are mixtures compositions and dosage forms containing the particles methods of using the particles eg to treat a disorder kits including the polymeragent conjugates and particles methods of making the polymeragent conjugates and particles methods of storing the particles and methods of analyzing the particles type application filed february   publication date july   applicant cerulean pharma inc inventors scott eliasof thomas c crawford geeti gangal lawrence alan reiter peisze ng treatment of cancer publication number  abstract provided are methods relating to compositions that include a cdptopoisomerase inhibitor eg a cdpcamptothecin or camptothecin derivative conjugate eg crlx type application filed october   publication date april   applicant cerulean pharma inc inventors edward g garmey scott eliasof polymeragent conjugates particles compositions and related methods of use publication number  abstract described herein are polymeragent conjugates and particles which can be used for example in the treatment of cancer also described herein are mixtures compositions and dosage forms containing the particles methods of using the particles eg to treat a disorder kits including the polymeragent conjugates and particles methods of making the polymeragent conjugates and particles methods of storing the particles and methods of analyzing the particles type application filed march   publication date april   applicant cerulean pharma inc inventors scott eliasof thomas c crawford geeti gangal lawrence alan reiter peisze ng polymerepothilone conjugates particles compositions and related methods of use publication number  abstract described herein are polymeragent conjugates and particles which can be used for example in the treatment of cancer or neurological deficits also described herein are mixtures compositions and dosage forms containing the particles methods of using the particles eg to treat a disorder kits including the polymeragent conjugates and particles methods of making the polymeragent conjugates and particles methods of storing the particles and methods of analyzing the particles type application filed may   publication date march   applicant cerulean pharma inc inventors scott eliasof thomas c crawford geeti gangal lawrence alan reiter peisze ng conjugates particles compositions and related methods publication number  abstract particles and conjugates for delivering nucleic acid agents compositions containing the particles the conjugates or both methods of using the particles the conjugates and the compositions type application filed february   publication date february   inventors scott eliasof oliver s fetzer jungyeon hwang patrick lim soo peisze ng sonke svenson donald bergstrom polymeragent conjugates particles compositions and related methods of use publication number  abstract described herein are polymeragent conjugates and particles which can be used for example in the treatment of cancer also described herein are mixtures compositions and dosage forms containing the particles methods of using the particles eg to treat a disorder kits including the polymeragent conjugates and particles methods of making the polymeragent conjugates and particles methods of storing the particles and methods of analyzing the particles type application filed july   publication date january   inventors thomas c crawford scott eliasof geeti gangal peisze ng lawrence alan reiter conjugates particles compositions and related methods publication number  abstract particles and conjugates for delivering nucleic acid agents compositions containing the particles the conjugates or both methods of using the particles the conjugates and the compositions type application filed april   publication date november   applicant cerulean pharma inc inventors scott eliasof oliver s fetzer jungyeon hwang patrick lim soo peisze ng sonke svenson donald e bergstrom polymeragent conjugates particles compositions and related methods of use publication number  abstract described herein are polymeragent conjugates and particles which can be used for example in the treatment of cancer also described herein are mixtures compositions and dosage forms containing the particles methods of using the particles eg to treat a disorder kits including the polymeragent conjugates and particles methods of making the polymeragent conjugates and particles methods of storing the particles and methods of analyzing the particles type application filed july   publication date november   inventors scott eliasof thomas c crawford geeti gangal lawrence alan reiter peisze ng conjugates particles compositions and related methods publication number  abstract particles and conjugates for delivering nucleic acid agents compositions containing the particles the conjugates or both methods of using the particles the conjugates and the compositions type application filed august   publication date september   applicant cerulean pharma inc inventors scott eliasof oliver s fetzer jungyeon hwang patrick lim soo peisze ng sonke svenson donald e bergstrom compositions and methods for treatment of autoimmune and other disease publication number  abstract provided are methods relating to the use of cdptherapeutic agent conjugates for the treatment of autoimmune disease inflammatory disease or cancer also provided are cdptherapeutic agent conjugates particles comprising cdptherapeutic agent conjugates and compositions comprising cdptherapeutic agent conjugates type application filed august   publication date march   applicant cerulean pharma inc inventor scott eliasof compositions and methods for treatment of autoimmune and other disease publication number  abstract provided are methods relating to the use of cdptherapeutic agent conjugates for the treatment of autoimmune disease inflammatory disease or cancer also provided are cdptherapeutic agent conjugates particles comprising cdptherapeutic agent conjugates and compositions comprising cdptherapeutic agent conjugates type application filed may   publication date december   inventor scott eliasof polymeragent conjugates particles compositions and related methods of use publication number  abstract described herein are polymeragent conjugates and particles which can be used for example in the treatment of cancer also described herein are mixtures compositions and dosage forms containing the particles methods of using the particles eg to treat a disorder kits including the polymeragent conjugates and particles methods of making the polymeragent conjugates and particles methods of storing the particles and methods of analyzing the particles type application filed january   publication date november   inventors thomas c crawford scott eliasof geeti gangal peisze ng lawrence alan reiter polymeragent conjugates particles compositions and related methods of use publication number  abstract described herein are polymeragent conjugates and particles which can be used for example in the treatment of cancer also described herein are mixtures compositions and dosage forms containing the particles methods of using the particles eg to treat a disorder kits including the polymeragent conjugates and particles methods of making the polymeragent conjugates and particles methods of storing the particles and methods of analyzing the particles type application filed september   publication date august   inventors scott eliasof thomas c crawford geeti gangal lawrence alan reiter peisze ng   next ask a lawyer question add details  additional details  ask question find a lawyer lawyers  get listed now get a free directory profile listing justia legal resources find a lawyer bankruptcy lawyers business lawyers criminal lawyers employment lawyers estate planning lawyers family lawyers personal injury lawyers more individuals bankruptcy criminal divorce dui estate planning family law personal injury more business business formation business operations employment intellectual property international trade real estate tax law more law students law schools admissions financial aid course outlines law journals blogs employment more us federal law us constitution us code regulations supreme court circuit courts district courts dockets  filings more us state law state constitutions state codes state case law california florida new york texas more other databases legal blogs legal forms gao reports product recalls patents trademarks countries more legal marketing websites blogs content social media local marketing paid ads cpcppc lawyer directory more   justia company terms of service privacy policy help marketing solutions cerulean announces promotion of scott eliasof phd to senior vice president and chief scientific officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street cerulean announces promotion of scott eliasof phd to senior vice president and chief scientific officer business wire oct    am edt cerulean pharma inc nasdaqceru a clinicalstage company developing nanoparticledrug conjugates ndcs today announced that scott eliasof phd has been promoted to the role of senior vice president and chief scientific officer effective immediately dr eliasof joined cerulean in  and was appointed vice president of research in  for the past ten years scott has been one of the driving forces behind our ndc innovations and we are pleased to expand his role at this critical time for our company said christopher d t guiffre president and chief executive officer of cerulean our versatile ndc platform created our proprietary pipeline including crlx and crlx and enabled our recentlyannounced collaboration with novartis which includes potential milestone payments for up to five targets we look forward to scotts leadership and continued contributions as we advance this pipeline and platform before joining cerulean in  dr eliasof was the director of the chemical biology platform at the broad institute directing a multidisciplinary team of professional scientists and technicians in the fields of synthetic chemistry analytical chemistry highthroughput screening computational science and software engineering this interdisciplinary organization is closely affiliated with the laboratory of stuart schreiber from harvard university and is one of the largest and oldest academic screening centers in the country prior to joining the broad institute dr eliasof worked at millennium pharmaceuticals where he managed scientific teams in cellular biology molecular biology neuroscience and bioinformatics for a largescale genomicsbased drug discovery program earlier in his career dr eliasof was at neurocrine biosciences where he played a key role in the exploration of glutamate transporters in the field of stroke and neurological disorders dr eliasof earned his bs from mit in electrical engineering phd from the university of california at berkeley in neuroscience and completed his postdoctoral fellowship at the vollum institute in portland oregon if you liked this article you might like stick to small fast trades until the feds out of the way betting on negative reaction to the fed has not worked well in the past rev shark mar    am edt  stocks poised for major breakoutsgold pharma and tech these stocks are within range of triggering breakout trades heres how to trade them from here roberto pedone dec    pm est cerulean pharma ceru stock tumbles on lead kidney cancer drug failure cerulean ceru announced today that its kidney cancer drug didnt meet its endpoint in a phase ii clinical trial rachel aldrich aug    am edt heres why cerulean pharma ceru stock is spiking today cerulean pharma ceru stock is jumping on wednesday afternoon following the publication of positive clinical data for its lead compound crlx which delivers an anticancer drug to tumors kaya yurieff mar    pm edt trending amazon and general electric are fridays smoking hot tickers amzn tsla sbux ge aapl here is why jim cramer doesnt want to buy more starbucks shares for action alerts plus amazon and starbucks team up to take down nasdaq apple investing billions in oled display buy chevron exxon mobil on solid dividends chart pinpoints when to load advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers cerulean announces promotion of scott eliasof phd to senior vice president and chief scientific officer  business wire cerulean announces promotion of scott eliasof phd to senior vice president and chief scientific officer october    am eastern daylight time waltham massbusiness wirecerulean pharma inc nasdaqceru a clinicalstage company developing nanoparticledrug conjugates ndcs today announced that scott eliasof phd has been promoted to the role of senior vice president and chief scientific officer effective immediately dr eliasof joined cerulean in  and was appointed vice president of research in  “for the past ten years scott has been one of the driving forces behind our ndc innovations and we are pleased to expand his role at this critical time for our company” said christopher d t guiffre president and chief executive officer of cerulean “our versatile ndc platform created our proprietary pipeline including crlx and crlx and enabled our recentlyannounced collaboration with novartis which includes potential milestone payments for up to five targets we look forward to scott’s leadership and continued contributions as we advance this pipeline and platform” before joining cerulean in  dr eliasof was the director of the chemical biology platform at the broad institute directing a multidisciplinary team of professional scientists and technicians in the fields of synthetic chemistry analytical chemistry highthroughput screening computational science and software engineering this interdisciplinary organization is closely affiliated with the laboratory of stuart schreiber from harvard university and is one of the largest and oldest academic screening centers in the country prior to joining the broad institute dr eliasof worked at millennium pharmaceuticals where he managed scientific teams in cellular biology molecular biology neuroscience and bioinformatics for a largescale genomicsbased drug discovery program earlier in his career dr eliasof was at neurocrine biosciences where he played a key role in the exploration of glutamate transporters in the field of stroke and neurological disorders dr eliasof earned his bs from mit in electrical engineering phd from the university of california at berkeley in neuroscience and completed his postdoctoral fellowship at the vollum institute in portland oregon about cerulean pharma the cerulean team is committed to improving treatment for people living with cancer we apply our dynamic tumor targeting™ platform to create a portfolio of ndcs designed to selectively attack tumor cells reduce toxicity by sparing the bodys normal cells and enable therapeutic combinations our first platformgenerated ndc clinical candidate crlx is in multiple clinical trials in combination with other cancer treatments all of which aim to unlock the power of combination therapy our second platformgenerated ndc clinical candidate crlx is in a phase a clinical trial for more information please visit httpwwwceruleanrxcom cautionary note on forward looking statements any statements in this press release about our future expectations plans and prospects including statements about the clinical development of our product candidates statements about the sufficiency of our cash and cash equivalents to fund our operations debt service and other scheduled expenditures and other statements containing the words anticipate believe continue could estimate expect hypothesize intend may plan potential predict project should target would and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including the uncertainties inherent in the initiation and completion of clinical trials availability and timing of data from ongoing and future clinical trials and the results of such trials whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials expectations for regulatory approvals availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the risk factors section of our quarterly report on form q filed with the securities and exchange commission on august   and in other filings that we make with the securities and exchange commission in addition any forwardlooking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date we specifically disclaim any obligation to update any forwardlooking statements included in this press release contacts cerulean pharma incnicole p jones director investor relations and corporate communicationsnjonesceruleanrxcomorargot partnerssusan kim  contacts cerulean pharma incnicole p jones director investor relations and corporate communicationsnjonesceruleanrxcomorargot partnerssusan kim  search advanced news search advanced news search log in sign up cerulean announces promotion of scott eliasof phd to senior vice president and chief scientific officer  pg  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street cerulean announces promotion of scott eliasof phd to senior vice president and chief scientific officer business wire oct    am edt about cerulean pharma the cerulean team is committed to improving treatment for people living with cancer we apply our dynamic tumor targeting™ platform to create a portfolio of ndcs designed to selectively attack tumor cells reduce toxicity by sparing the bodys normal cells and enable therapeutic combinations our first platformgenerated ndc clinical candidate crlx is in multiple clinical trials in combination with other cancer treatments all of which aim to unlock the power of combination therapy our second platformgenerated ndc clinical candidate crlx is in a phase a clinical trial for more information please visit httpwwwceruleanrxcom cautionary note on forward looking statements any statements in this press release about our future expectations plans and prospects including statements about the clinical development of our product candidates statements about the sufficiency of our cash and cash equivalents to fund our operations debt service and other scheduled expenditures and other statements containing the words anticipate believe continue could estimate expect hypothesize intend may plan potential predict project should target would and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including the uncertainties inherent in the initiation and completion of clinical trials availability and timing of data from ongoing and future clinical trials and the results of such trials whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials expectations for regulatory approvals availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the risk factors section of our quarterly report on form q filed with the securities and exchange commission on august   and in other filings that we make with the securities and exchange commission in addition any forwardlooking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date we specifically disclaim any obligation to update any forwardlooking statements included in this press release if you liked this article you might like stick to small fast trades until the feds out of the way betting on negative reaction to the fed has not worked well in the past rev shark mar    am edt  stocks poised for major breakoutsgold pharma and tech these stocks are within range of triggering breakout trades heres how to trade them from here roberto pedone dec    pm est cerulean pharma ceru stock tumbles on lead kidney cancer drug failure cerulean ceru announced today that its kidney cancer drug didnt meet its endpoint in a phase ii clinical trial rachel aldrich aug    am edt heres why cerulean pharma ceru stock is spiking today cerulean pharma ceru stock is jumping on wednesday afternoon following the publication of positive clinical data for its lead compound crlx which delivers an anticancer drug to tumors kaya yurieff mar    pm edt trending amazon and general electric are fridays smoking hot tickers amzn tsla sbux ge aapl here is why jim cramer doesnt want to buy more starbucks shares for action alerts plus amazon and starbucks team up to take down nasdaq apple investing billions in oled display buy chevron exxon mobil on solid dividends chart pinpoints when to load advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers cerulean announces promotion of scott eliasof phd to senior vice president and chief scientific officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       cerulean ceru announces promotion of scott eliasof phd to senior vice president and chief scientific officer tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs waltham massbusiness wirecerulean pharma inc nasdaqceru a clinicalstage company developing nanoparticledrug conjugates ndcs today announced that scott eliasof phd has been promoted to the role of senior vice president and chief scientific officer effective immediately dr eliasof joined cerulean in  and was appointed vice president of research in  “our versatile ndc platform created our proprietary pipeline including crlx and crlx and enabled our recentlyannounced collaboration with novartis which includes potential milestone payments for up to five targets we look forward to scott’s leadership and continued contributions as we advance this pipeline and platform” “for the past ten years scott has been one of the driving forces behind our ndc innovations and we are pleased to expand his role at this critical time for our company” said christopher d t guiffre president and chief executive officer of cerulean “our versatile ndc platform created our proprietary pipeline including crlx and crlx and enabled our recentlyannounced collaboration with novartis which includes potential milestone payments for up to five targets we look forward to scott’s leadership and continued contributions as we advance this pipeline and platform” before joining cerulean in  dr eliasof was the director of the chemical biology platform at the broad institute directing a multidisciplinary team of professional scientists and technicians in the fields of synthetic chemistry analytical chemistry highthroughput screening computational science and software engineering this interdisciplinary organization is closely affiliated with the laboratory of stuart schreiber from harvard university and is one of the largest and oldest academic screening centers in the country prior to joining the broad institute dr eliasof worked at millennium pharmaceuticals where he managed scientific teams in cellular biology molecular biology neuroscience and bioinformatics for a largescale genomicsbased drug discovery program earlier in his career dr eliasof was at neurocrine biosciences where he played a key role in the exploration of glutamate transporters in the field of stroke and neurological disorders dr eliasof earned his bs from mit in electrical engineering phd from the university of california at berkeley in neuroscience and completed his postdoctoral fellowship at the vollum institute in portland oregon about cerulean pharma the cerulean team is committed to improving treatment for people living with cancer we apply our dynamic tumor targeting™ platform to create a portfolio of ndcs designed to selectively attack tumor cells reduce toxicity by sparing the bodys normal cells and enable therapeutic combinations our first platformgenerated ndc clinical candidate crlx is in multiple clinical trials in combination with other cancer treatments all of which aim to unlock the power of combination therapy our second platformgenerated ndc clinical candidate crlx is in a phase a clinical trial for more information please visit httpwwwceruleanrxcom cautionary note on forward looking statements any statements in this press release about our future expectations plans and prospects including statements about the clinical development of our product candidates statements about the sufficiency of our cash and cash equivalents to fund our operations debt service and other scheduled expenditures and other statements containing the words anticipate believe continue could estimate expect hypothesize intend may plan potential predict project should target would and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including the uncertainties inherent in the initiation and completion of clinical trials availability and timing of data from ongoing and future clinical trials and the results of such trials whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials expectations for regulatory approvals availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the risk factors section of our quarterly report on form q filed with the securities and exchange commission on august   and in other filings that we make with the securities and exchange commission in addition any forwardlooking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date we specifically disclaim any obligation to update any forwardlooking statements included in this press release contacts cerulean pharma incnicole p jones director investor relations and corporate communicationsnjonesceruleanrxcomorargot partnerssusan kim  read at biospacecom related news struggling cerulean ceru inks deal worth  billion with pharma giant novartis ag nvs meet the cancer scientist leading genentech rhhbys first podcast cerulean ceru announces technology platform collaboration top  european biotech entrepreneurs under  in  cerulean ceru announces  million firm commitment atthemarket stock purchase agreement with aspire capital fund llc biotech goes hollywood again as jennifer lopez set to produce new show about crispr geneediting trial failure prompts cerulean ceru to pink slip  of workforce despite bashing the pharma industry more than half of biotech execs surveyed still support hillary clinton cerulean ceru shares decimated as renal cell carcinoma drug comes up short in midstage study former novartis ag nvs cart scientist jumps to txcell to lead cartreg research programs please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • cerulean pharma inc   • biotechpharma  personnel                 stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top vz log in for events urbn urbn syna ll hp log in for events alks cvrr cvrr esnd find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  am et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map  stock research  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries the symbol you entered cannot be found check the information and try again or use symbol lookup to see if a valid symbol exists for the company you are trying to find copyright – fmr llc  all rights reserved  terms of use privacy security site map  microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft unavailable  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries this feature is temporarily unavailable copyright – fmr llc  all rights reserved  terms of use privacy security site map  stock ticker symbol lookup  marketwatch bulletin investor alert new york markets close in market snapshot winners and losers symbol lookup name country united states all canada australia france germany hong kong italy japan netherlands new zealand norway south africa spain sweden switzerland united kingdom security type all stock fund index currency symbol company exchange cern cerner corp nasdaq now servicenow inc nyse siri sirius xm holdings inc nasdaq srpt sarepta therapeutics inc nasdaq cone cyrusone inc nasdaq cern cerner corp nasdaq xrx xerox corp nyse crus cirrus logic inc nasdaq serv servicemaster global holdings inc nyse sci service corp international nyse now servicenow inc nyse cone cyrusone inc nasdaq srpt sarepta therapeutics inc nasdaq srci src energy inc us crus cirrus logic inc nasdaq xrx xerox corp nyse siri sirius xm holdings inc nasdaq siri sirius xm holdings inc nasdaq shld sears holdings corp nasdaq srg seritage growth properties cl a nyse now servicenow inc nyse sfbs servisfirst bancshares inc nasdaq siri sirius xm holdings inc nasdaq saia saia inc nasdaq cern cerner corp btt srpt sarepta therapeutics inc nasdaq now servicenow inc btt sci service corp international nyse cern cerner corp nasdaq serv servicemaster global holdings inc nyse siri sirius xm holdings inc btt now servicenow inc nyse now servicenow inc nyse cir circor international inc nyse now servicenow inc nyse cern cerner corp nasdaq now servicenow inc nyse srpt sarepta therapeutics inc btt xrx xerox corp btt sfbs servisfirst bancshares inc nasdaq crus cirrus logic inc nasdaq xrx xerox corp nyse cone cyrusone inc btt cone cyrusone inc nasdaq crus cirrus logic inc btt cern cerner corp nasdaq sgry surgery partners inc nasdaq shld sears holdings corp nasdaq cers cerus corp nasdaq saia saia inc nasdaq most popular  the dark side of cruises  cocacola to replace coke zero in us  market snapshot dow ends at record but tech slump weighs on sp  nasdaq  if you can buy only one stock or etf make it this one  barrons buzz how to fix wall street and bankers pay find a broker partner center » log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pthese companies spent over  billion buying back shares while their ceos were dumping them pstock market edges lower on track for weekly losses awells fargo will pay  million to overcharged auto loan consumers agold aims for thirdweekly gain as dollar holds loss after gdp report acharting a bulltrend whipsaw nasdaq’s key reversal fuels sector rotation again aa global investment strategist offers up a summer reading list to make you a better investor athis fund strategist says there’s at least one way companies can survive amazon’s onslaught awells fargo fda plan to lower nicotine could be opportunity for altria philip morris ahere’s one trump fan who might make you some money awhat the solar eclipse on aug  will mean for stocks ayou’ll save money on gas with the tesla model  but you may end up paying more elsewhere asurprise those ‘great’ companies generally turn out to be meh  or duds athis quant pro and card counter says gambling can make you a better investor awatch out ‘kids’ are making the most money in this stock market athis basic balanced index fund is beating the hedge fund averages agold prices trade near session highs after reports of missile test in north korea aaug gold climbs by  or  to oz aweekend roundup amazon’s spending  surviving amazon  caterpillar’s comeback atesla’s model  will be launched with panacheand a partylater friday awhat we can learn about dealing with setbacks at work from the obamacare repeal failure loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  scott eliasof  former directorchemical biology platform at massachusetts institute of technology news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink scott eliasof former directorchemical biology platform at massachusetts institute of technology overview in the news relationships paths education career history scott eliasof former directorchemical biology platform at massachusetts institute of technology overview age  born  number of relationships this person is connected to  people in the news see more marketline newswire october   cerulean announces promotion of scott eliasof phd to senior vice president and chief scientific officer business wire october   cerulean announces promotion of scott eliasof phd to senior vice president and chief scientific officer business wire october   cerulean announces poster presentations at the  aacrncieortc international conference on molecular targets and cancer therapeutics pr newswire september   cerulean announces publication of data from companys lead candidate crlx in proceedings of the national academy of sciences pnas relationships see details ram sasisekharan scientific founder at visterra inc george m church professor of health sciences  technology at massachusetts institute of technology marcia nizzari lecturer at boston university steven e hyman directorstanley center psychiatric research at massachusetts institute of technology christopher d t guiffre former president  chief executive officer at cerulean pharma inc oliver fetzer chief executive officer at synthetic genomics inc karen l roberts professional at the financial executives institute edward garmey partner at alacrita llp gregg d beloff former chief financial officer at seres therapeutics inc alan crane cofounder at arsia therapeutics see  more listings with relsci professional start my free trial ➤ see  more paths to scott eliasof scott eliasof you connections via relationship science scott eliasof sync your contacts to see how you can connect with scott eliasof start my free trial ➤ see more educational background   university of california  berkeley university of california berkeley national rankings in a national research council analysis of  doctoral programs at american universities  berkeley programs place among the top  nationwide faculty awards and honors there are  nobel laureates  macarthur fellows and  pulitzer prize winners among the current faculty history of uc berkeley historical highlights arranged by topic following the campuss development — from ucs founding in  to a turnofthecentury building boom a research explosion in the s the free speech movement of the s and berkeleys key role today in science and technology revolutions timeline of discoveries and contributions by uc berkeley scholars traditions of cal who was the angel of death whats with the big c up there in the hills — and why is it sometimes green who wears oskis jolly bear head and size  yellow sweater tours and webcams check out whats happening on sproul plaza the campuss true heart see stunning live views of the bay area from the lawrence hall of sciences perch in the berkeley hills chancellor and administration information on chancellor robert birgeneau executive vice chancellor and provost george w breslauer and how the university is organized organizational charts are included uc system overview and links on the campuses laboratories and medical centers that comprise ucs public educational system as well as ucs k partnerships economic impact and agriculture and environmental resources bs in electrical engineering  massachusetts institute of technology massachusetts institute of technology mit is a private research university located in cambridge massachusetts united states mit has five schools and one college containing a total of  academic departments with a strong emphasis on scientific engineering and technological education and research founded in  in response to the increasing industrialization of the united states the institute used a polytechnic university model and stressed laboratory instruction mit was elected to the association of american universities in  career history chief scientific officer  senior vice president    cerulean pharma inc cerulean pharma inc is a clinicalstage oncologyfocused company which provides proprietary dynamic tumor targeting platform to develop differentiated therapies it specializes in the design and development of nanopharmaceuticals ceruleans nanopharmaceuticals are drugcontaining nanoparticles designed and optimized to enhance therapeutic agents ranging from small molecules to therapeutic peptides and rnai molecules the company was founded by alan l crane and ram sasisekharn on november   and is headquartered in waltham ma directorchemical biology platform prior massachusetts institute of technology massachusetts institute of technology mit is a private research university located in cambridge massachusetts united states mit has five schools and one college containing a total of  academic departments with a strong emphasis on scientific engineering and technological education and research founded in  in response to the increasing industrialization of the united states the institute used a polytechnic university model and stressed laboratory instruction mit was elected to the association of american universities in  directorchemical biology platform prior harvard university harvard was established in  and it is the oldest institution of higher education in the united states the university which is based in cambridge and boston massachusetts has an enrollment of over  degree candidates including undergraduate graduate and professional students the university has twelve degreegranting schools in addition to the radcliffe institute for advanced study directorchemical biology platform prior the broad institute inc the broad institute evolved from a decade of informal and successful research collaborations among scientists in the mit and harvard communities in  the whitehead institutemit center for genome research wicgr was founded and it soon became an international leader in the field of genomics and a flagship of the human genome project as early as  wicgr scientists recognized the need to bring the power of genomics to the understanding of human disease it launched pilot projects in genomic medicine forming an unofficial collaborative network among scientists from across mit and harvard who pioneered new approaches to cancer and human genetics in parallel harvard medical schoolbased scientists established the institute of chemistry and cell biology iccb in  to facilitate the pursuit of chemical genetics as an academic discipline and a tool to further understand human biology and disease in  the iccb was awarded an initiative for chemical genetics icg grant from the national cancer institute and its successful investigatorinitiated screening program facilitated small molecule screening projects for more than  research groups worldwide these projects demonstrated the power of enabling scientists to collaborate to tackle the major challenges in molecular medicine it was clear that a new type of formal organization was required — open collaborative interdisciplinary and able to organize projects at any scale in addition it was important that the complementary expertise of the genomic scientists and the chemical biologists across mit and harvard be brought together in one place to drive the transformation of medicine with molecular knowledge discussions in  among eli and edythe broad mit harvard and its affiliated hospitals and the whitehead institute shaped the vision for this new institute the extraordinary generosity of eli and edythe broad through their founding gift of  million later doubled to  million made it possible to formally announce the new institute in june  and to launch it in may  less than four years after its launch the broads gave an unprecedented gift of  million in september  to permanently endow the institute providing longterm sustainability for its unique model of collaborative interinstitutional research postdoctoral fellow prior oregon health  science university  vollum institute the vollum institute is dedicated to the study of the molecular basis of nervous system function with pioneering studies of synaptic modulation neurotransmitter secretion gene regulation protein trafficking protein structure and neuronal development investigators at the vollum pursue basic science research that will have substantial impact on our understanding of conditions such as multiple sclerosis drug addiction autism and stroke professional prior neurocrine biosciences inc neurocrine biosciences inc operates as a product based biopharmaceutical company it discovers develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders the company was founded by kevin c gorman and wylie w vale on january  and is headquartered in san diego ca professional prior takeda oncology co takeda oncology co operates as a biopharmaceutical company its products include ninlaro and velcade the company was founded in  and is headquartered in cambridge ma other affiliations scott eliasof is affiliated with cerulean pharma inc massachusetts institute of technology harvard university the broad institute inc oregon health  science university  vollum institute neurocrine biosciences inc takeda oncology co youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ cerulean announces promotion of scott eliasof phd to senior vice president and chief scientific officerhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets close in  hrs  minssp  dow  nasdaq stocks to watchintel impresses with strong quarter starbucks and mattel shares are tankingcerulean announces promotion of scott eliasof phd to senior vice president and chief scientific officerbusiness wireoctober  reblogsharetweetsharewaltham massbusiness wirecerulean pharma inc ceru a clinicalstage company developing nanoparticledrug conjugates ndcs today announced that scott eliasof phd has been promoted to the role of senior vice president and chief scientific officer effective immediately dr eliasof joined cerulean in  and was appointed vice president of research in “for the past ten years scott has been one of the driving forces behind our ndc innovations and we are pleased to expand his role at this critical time for our company” said christopher d t guiffre president and chief executive officer of cerulean “our versatile ndc platform created our proprietary pipeline including crlx and crlx and enabled our recentlyannounced collaboration with novartis which includes potential milestone payments for up to five targets we look forward to scott’s leadership and continued contributions as we advance this pipeline and platform”before joining cerulean in  dr eliasof was the director of the chemical biology platform at the broad institute directing a multidisciplinary team of professional scientists and technicians in the fields of synthetic chemistry analytical chemistry highthroughput screening computational science and software engineering this interdisciplinary organization is closely affiliated with the laboratory of stuart schreiber from harvard university and is one of the largest and oldest academic screening centers in the country prior to joining the broad institute dr eliasof worked at millennium pharmaceuticals where he managed scientific teams in cellular biology molecular biology neuroscience and bioinformatics for a largescale genomicsbased drug discovery program earlier in his career dr eliasof was at neurocrine biosciences where he played a key role in the exploration of glutamate transporters in the field of stroke and neurological disorders dr eliasof earned his bs from mit in electrical engineering phd from the university of california at berkeley in neuroscience and completed his postdoctoral fellowship at the vollum institute in portland oregonabout cerulean pharmathe cerulean team is committed to improving treatment for people living with cancer we apply our dynamic tumor targeting™ platform to create a portfolio of ndcs designed to selectively attack tumor cells reduce toxicity by sparing the bodys normal cells and enable therapeutic combinations our first platformgenerated ndc clinical candidate crlx is in multiple clinical trials in combination with other cancer treatments all of which aim to unlock the power of combination therapy our second platformgenerated ndc clinical candidate crlx is in a phase a clinical trial for more information please visit httpwwwceruleanrxcomcautionary note on forward looking statementsany statements in this press release about our future expectations plans and prospects including statements about the clinical development of our product candidates statements about the sufficiency of our cash and cash equivalents to fund our operations debt service and other scheduled expenditures and other statements containing the words anticipate believe continue could estimate expect hypothesize intend may plan potential predict project should target would and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including the uncertainties inherent in the initiation and completion of clinical trials availability and timing of data from ongoing and future clinical trials and the results of such trials whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials expectations for regulatory approvals availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the risk factors section of our quarterly report on form q filed with the securities and exchange commission on august   and in other filings that we make with the securities and exchange commission in addition any forwardlooking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date we specifically disclaim any obligation to update any forwardlooking statements included in this press releaseview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nextverizon soars on beat starbucks big china deal astrazeneca sinks as drug trial disappointsyahoo finance ways to avoid running out of money in retirementfisher investmentssponsoredjohn elway promoted to president of football operationsgmprofootball talk on nbc sportstrump divorce former nfl cheerleader and florida state attorney split over us presidentthe telegraphwind projects in peril as indian states rethink purchasesbloombergengineer finds pattern makes millions in stocksmoney morningsponsoredamazons alexa boss says the ultimate goal is to reinvent the star trek computerbusiness insidertrump’s unwitting legacy could be universal health coverageyahoo financeairbnb sued by woman who says she was sexually assaulted by superhostthe guardianzuckerberg wifes ambitious secret finally exposedunewzmesponsoredtax cuts just got more likelyyahoo financepogue the business of keeping  kitchens out of landfillsyahoo finance videothe average person would pay  more for commercialfree cableyahoo financediscover it  out of  avg by k customersdiscover cardsponsoredsean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insiderintel impresses with strong quarter starbucks and mattel shares are tankingyahoo financetrump rages at republicans as john mccain kills obamacare repeal billsuzy q trump promised he had a healthcare bill that would lower costs expand coverage and offer more choices where is his bill time to put up or shut upjoin the conversation